NYSE •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization11.22 mln
Float14.28 mln
Earnings Date08/18/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-3.89
Highly reliable
1-Year Forecast
5.25
Transformational upside
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
2.15
Very high leverage
Dividend Yield
0.00%
No dividend
Business Description
AIM ImmunoTech Inc. is a US-based medical research company working to develop treatments for cancer, viral infections, and immune system disorders. Its two main products are Ampligen, used to treat chronic fatigue syndrome, and Alferon N Injection, which targets genital warts. The company is also exploring Ampligen as a potential therapy for a wide range of cancers and conditions including HIV, Hepatitis B, and COVID-19. Founded in 1966 and based in Ocala, Florida, the company operated under the name Hemispherx Biopharma Inc. before rebranding in 2019.
